Cibus shares surge 18.37% after-hours after Canaccord Genuity issues "Buy" rating.

Cibus surged 18.37% in after-hours trading following a "Buy" rating from Canaccord Genuity Group, as reported by GlobeNewswire on December 11, 2025. This analyst upgrade, a rare positive catalyst for the biotech firm, signaled renewed institutional confidence in its gene-editing technology and commercial prospects. While other recent news, such as board appointments and conference presentations, provided incremental support, the rating directly aligned with the stock’s sharp after-hours rally, reflecting heightened investor optimism about its pipeline and strategic direction.